Showing 901-910 of 9594 results for "".
Shared Decision-making Approach with Biologics
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37162/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, discusses the expanding biologic landscape for atopic dermatitis and how to select the optimal therapeutic for each patientIncreased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisDermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://reachmd.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privJournal Club: Dupilumab and Atopic March
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedSeborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fDermWire TV Extra: Spironolactone on TikTok
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-spironolactone-on-tiktok/33016/George Washington University clinical instructor of Dermatology Emily Murphy, MD, and medical student Savanna Vidal discuss their research regarding the quality and reliability of information on TikTok about spironolactone for acne treatment.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at Take